Qube Research & Technologies LTD Bio Line Rx Ltd. Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
A detailed history of Qube Research & Technologies LTD transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 13,035 shares of BLRX stock, worth $43,406. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,035
Previous 13,035
-0.0%
Holding current value
$43,406
Previous $7,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BLRX
# of Institutions
39Shares Held
3.22MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$2.89 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.72 Million4.05% of portfolio
-
Envestnet Asset Management Inc239KShares$796,4890.0% of portfolio
-
Morgan Stanley New York, NY198KShares$657,7980.0% of portfolio
-
Values First Advisors, Inc.166KShares$554,2750.02% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $205M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...